Mark Cunningham

Title: Mark Cunningham - Innovator in Pharmaceutical Chemistry

Introduction

Mark Cunningham is a notable inventor based in San Diego, CA. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that inhibit dihydrofolate reductase (DHFR). His work is crucial in addressing various cell proliferative diseases and infections.

Latest Patents

Mark Cunningham holds a patent for dihydrofolate reductase inhibitors. The patent provides compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R, and Z are as described in the disclosure. This innovation includes pharmaceutical compositions and methods for inhibiting DHFR activity, as well as methods for treating autoimmune diseases, inflammatory diseases, and infections caused by bacteria, fungi, or parasites.

Career Highlights

Cunningham is currently associated with Trius Therapeutics, Inc., where he applies his expertise in drug development. His work at Trius Therapeutics focuses on creating effective treatments for serious infections, showcasing his commitment to advancing medical science.

Collaborations

Throughout his career, Mark has collaborated with esteemed colleagues such as Zhiyong Chen and Christopher John Creighton. These partnerships have enhanced his research and contributed to the success of his projects.

Conclusion

Mark Cunningham's innovative work in pharmaceutical chemistry, particularly in developing DHFR inhibitors, highlights his significant impact on medical research and treatment options. His contributions continue to pave the way for advancements in the field.